to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
Entrepreneurs looking for seed capital should consider Toronto TSX Venture Exchange's Capital Pool Company (CPC) program, which allows companies to go public by merging with a CPC.
When a company needs to raise capital, it can issue stocks, warrants or options, bonds, notes or debentures. Know the functions and advantages of each before you choose.
Local investing could be the answer to the problem of dealing with big banks and the way they do business. Read more about this funding alternative for startups.
Valuation negotiations between entrepreneurs and investors are often contentious. Such valuations rarely stray from the $1 million to $3 million range for seed/startup companies that angels expect to grow to $50 million to $100 million over five to eight years. Angels are most concerned about the management team's ability to rapidly grow the company and about helping the entrepreneur achieve these growth objectives.
When pitching a potential investor, it is important to understand not only what they want to hear, but more importantly what they don't. Avoid these typical mistakes that many entrepreneurs make when seeking funding from angels and venture capitalists.
This exceptional article offers insightful explanation and key details of how angel investors determine valuations, why entrepreneurs and investors often have different perspectives for angel returns, and what steps angels and entrepreneurs can take to quickly find common ground on this critical topic.
Retired serial entrepreneur Steve Blank interviews MissionPoint Capital co-founder Jesse Fink. The two discuss the manifold investment opportunities in alternative energies and environmental conservation.
Entrepreneurs must identify ways to exit a business at the onset, which enables efforts to be directed to a goal, writes the builder of two companies. The author, now a venture capitalist, outlines four steps for doing so.
What's the best strategy for developing and launching a new medical device? The uncertainty of the regulatory and reimbursement environment in the United States has made venture capitalists wary of investing in new medical device companies, but that doesn't mean all is lost.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.